首页> 中文期刊> 《四川医学》 >Graves病伴发甲状腺毒症性心脏病128例临床分析

Graves病伴发甲状腺毒症性心脏病128例临床分析

         

摘要

Objective To explore the prevalence , clinical feature and risk factors of hyperthyroid heart disease and enable correct treatment. Methods Clinical datas of 1443 cases of Graves disease including 128 cases of hyperthyroid heart disease were investigated retrospectively from April to June in 2009. Results The prevalence of hyperthyroid heart disease was 8.9% , and the total effective rate after radioiodine-131 therapy were 96. 9%. Logistic regression analysis showed that the FT4, male, age and progress are the independent risk factors of hyperthyroid heart disease, their OR values are 3. 15 X2. 17 ^1. 71 and 1. 57 respectively. Conclusion Hyperthyroid heart disease is common in GD patients, it should be paid attention to those patients with higher FT4, male,elder and longer course of disease. Radioiodine-131 therapy should be the first choice for those patients.%目的 分析甲状腺毒症性心脏病的发病率、临床特征、危险因素和131Ⅰ治疗效果.方法 回顾性分析2009年4~6月连续收治的1443例GD患者(甲状腺毒症性心脏病组128例,单纯Graves病组1315例)的临床资料,包括一般资料、临床表现、治疗预后、心电图和超声心动图变化.结果 甲状腺毒症性心脏病的整体发病率约8.9%,131Ⅰ治疗后总有效率96.9%.Logistic回归分析发现FT4越高、男性患者、年龄越大和病程越长者出现甲状腺毒症性心脏病的危险越大,其OR值分别为3.15、2.17、1.71和1.57.结论 131Ⅰ治疗甲亢性心脏病安全、有效,可作为首选治疗方法;高FT4水平、男性、年龄大和病程较长是Graves病患者出现甲亢性心脏病的独立危险因素,应给予必要的预防与治疗.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号